Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

STEGLUJAN

×

Overview

What is STEGLUJAN?

STEGLUJAN (ertugliflozin and sitagliptin) tablet for oral use contains ertugliflozin L-pyroglutamic acid, a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor.



What does STEGLUJAN look like?



What are the available doses of STEGLUJAN?

Tablets:

What should I talk to my health care provider before I take STEGLUJAN?

How should I use STEGLUJAN?

STEGLUJAN™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.

Recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning, with or without food. ()

Increase dose to 15 mg ertugliflozin/100 mg sitagliptin once daily in those tolerating STEGLUJAN and needing additional glycemic control. ()

Assess renal function before initiating STEGLUJAN and periodically thereafter ():


What interacts with STEGLUJAN?

Sorry No Records found


What are the warnings of STEGLUJAN?

Sorry No Records found


What are the precautions of STEGLUJAN?

Sorry No Records found


What are the side effects of STEGLUJAN?

Sorry No records found


What should I look out for while using STEGLUJAN?

Severe renal impairment, end stage renal disease, or dialysis. (, )

History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. (, , )

History of serious hypersensitivity reaction to ertugliflozin. ()


What might happen if I take too much STEGLUJAN?


How should I store and handle STEGLUJAN?

Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the hospital unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the hospital unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the hospital unit-dose blister packages in the carton until contents have been used.STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500STEGLUJAN (ertugliflozin and sitagliptin) tablets are available in the strengths listed below:STEGLUJAN 5 mg/100 mg: ertugliflozin 5 mg and sitagliptin 100 mg tablets are beige, almond-shaped, debossed with "554" on one side and plain on the other side. They are supplied as follows:NDC 0006-5367-03 unit-of-use bottles of 30NDC 0006-5367-06 unit-of-use bottles of 90NDC 0006-5367-07 bulk bottles of 500STEGLUJAN 15 mg/100 mg: ertugliflozin 15 mg and sitagliptin 100 mg tablets are brown, almond-shaped, debossed with "555" on one side and plain on the other side. They are supplied as follows:NDC 0006-5368-03 unit-of-use bottles of 30NDC 0006-5368-06 unit-of-use bottles of 90NDC 0006-5368-07 bulk bottles of 500


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
Severe renal impairment, end stage renal disease, or dialysis. (, )

History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. (, , )

History of serious hypersensitivity reaction to ertugliflozin. ()

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Antagonism has been demonstrated between clindamycin and erythromycin . Because of possible clinical significance, these two drugs should not be administered concurrently.

There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking sitagliptin, a component of STEGLUJAN. After initiation of STEGLUJAN, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, STEGLUJAN should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN.

The following important adverse reactions are described elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).